Generic Name and Formulations:
Methylnaltrexone bromide 150mg; tabs.
Valeant Pharmaceuticals, Inc
Indications for RELISTOR:
Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation.
Discontinue all maintenance laxatives prior to initiation; may be used if suboptimal methylnaltrexone response after 3 days. Reevaluate if opioid regimen is changed. Take on an empty stomach with water ≥30mins before first meal of day. 450mg once daily in the AM. Moderate or severe renal (CrCl<60mL/min) or hepatic (Child-Pugh B or C) impairment: 150mg once daily.
Known or suspected GI obstruction and at increased risk of recurrent obstruction.
Discontinue if concurrent opioid pain medication is also discontinued. GI perforation; monitor for severe, persistent, or worsening abdominal pain; discontinue if occurs. Discontinue if severe or persistent diarrhea occurs. Increased risk of opioid withdrawal and/or reduced analgesia in those with blood-brain barrier disruptions; monitor for symptoms. Bowel movement may occur within 30 mins of dosing. Elderly. Pregnancy. Nursing mothers: not recommended.
Potential additive effects and increased risk of opioid withdrawal with concomitant other opioid antagonists; avoid.
Opioid antagonist (peripheral).
Abdominal pain, flatulence, nausea, dizziness, diarrhea, headache, abdominal distention, vomiting, hyperhidrosis, anxiety, muscle spasms, rhinorrhea, chills, tremor, hot flush; GI perforation, opioid withdrawal.
Tabs—60, 90; Single-use vial (12mg/0.6mL)—1; Prefilled syringes (8mg/0.4mL)—7; Prefilled syringes (12mg/0.6mL)—1, 7
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations